Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents.
Karin StadlbauerBarbara BrunmairZsuzsanna LehnerImmanuel AdorjanThomas SchererAnton LugerLeonhardt BauerClemens FürnsinnPublished in: Diabetes, obesity & metabolism (2017)
55P0251 is a novel compound that potently counteracts hyperglycaemia in rodents via amplification of glucose-stimulated insulin release.